Marinus Pharmaceuticals Inc (MEX:MRNS)
MXN 5.25 0 (0%) Market Cap: 414.73 Mil Enterprise Value: 694.13 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 26/100

Marinus Pharmaceuticals Inc at 38th Annual J.P Morgan Healthcare Conference Transcript

Jan 16, 2020 / 07:00PM GMT
Rumen Vasilev;J.P. Morgan Securities LLC;Investment Banking Associate

Good morning, everyone. Thanks for coming. My name is Rumen Vasilev, and I'm a member of the JPMorgan team. It is my pleasure to introduce the CEO of Marinus, Scott Braunstein.

Scott Braunstein
Marinus Pharmaceuticals, Inc. - CEO & Director

Well, good morning, and thank you all for coming. It's Thursday. I know it's been a long week for many of us. It's raining outside, so thrilled to have you here today. And I'm going to jump right in because we have quite a bit of material to cover.

That's our forward-looking statement, and you can find that on our website.

And let me start by telling you a little bit about our company, Marinus Pharmaceuticals. We have been studying ganaxolone, a GABA modulator, for many years. But since taking over the company a little less than a year ago as executive chairman and now CEO, we are focusing our efforts in the epilepsy space. We are fortunate enough to have several formulations of ganaxolone, both IV and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot